Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020
Debt
Debt-to-Equity Ratio-1.82
Current Ratio2.83
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-1.81
Forward P/E Ratio-3.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.82 million
Price / Sales27.28
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-92.50
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-430.21%
Return on Equity-652.66%
Return on Assets-115.03%
Miscellaneous
Employees313
Outstanding Shares247,990,000
Market Cap$453.82 million
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) issued its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. The biopharmaceutical company earned $12.25 million during the quarter, compared to analysts' expectations of $10.20 million. Synergy Pharmaceuticals had a negative net margin of 430.21% and a negative return on equity of 652.66%. View Synergy Pharmaceuticals' Earnings History.
When is Synergy Pharmaceuticals' next earnings date?
What price target have analysts set for SGYP?
7 analysts have issued 1-year price targets for Synergy Pharmaceuticals' shares. Their forecasts range from $2.50 to $13.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $7.9286 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.
What is the consensus analysts' recommendation for Synergy Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 56,199,175 shares, an increase of 2.2% from the July 13th total of 55,006,108 shares. Based on an average trading volume of 2,101,392 shares, the short-interest ratio is presently 26.7 days. Approximately 22.8% of the shares of the stock are sold short. View Synergy Pharmaceuticals' Current Options Chain.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include Enanta Pharmaceuticals (ENTA), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), ACADIA Pharmaceuticals (ACAD), Insmed (INSM), Puma Biotechnology (PBYI), TESARO (TSRO), Allakos (ALLK), ARMO Biosciences (ARMO), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Myovant Sciences (MYOV).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Dr. Gary S. Jacob, Exec. Chairman (Age 71)
- Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
- Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)
- Dr. Patrick H. Griffin, Exec. VP & Chief Medical Officer (Age 63)
- Mr. Marino Garcia, Exec. VP & Chief Strategy Officer (Age 51)
Has Synergy Pharmaceuticals been receiving favorable news coverage?
Press coverage about SGYP stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Synergy Pharmaceuticals.
Who are Synergy Pharmaceuticals' major shareholders?
Synergy Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.81%), Hikari Power Ltd (0.93%), Schwab Charles Investment Management Inc. (0.53%), Bank of New York Mellon Corp (0.43%), Bank of America Corp DE (0.10%) and Mackay Shields LLC (0.08%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.
Which major investors are selling Synergy Pharmaceuticals stock?
Which major investors are buying Synergy Pharmaceuticals stock?
SGYP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Hikari Power Ltd, Chicago Equity Partners LLC, Schwab Charles Investment Management Inc., Mackay Shields LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $1.85.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $453.82 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
